165 related articles for article (PubMed ID: 37775682)
41. Spotlight on insulin detemir in type 1 and 2 diabetes mellitus.
Chapman TM; Perry CM
BioDrugs; 2005; 19(1):67-9. PubMed ID: 15691219
[TBL] [Abstract][Full Text] [Related]
42. Insulin glargine versus neutral protamine Hagedorn insulin for treatment of diabetes in pregnancy.
Smith JG; Manuck TA; White J; Merrill DC
Am J Perinatol; 2009 Jan; 26(1):57-62. PubMed ID: 18979406
[TBL] [Abstract][Full Text] [Related]
43. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes.
Philis-Tsimikas A; Charpentier G; Clauson P; Ravn GM; Roberts VL; Thorsteinsson B
Clin Ther; 2006 Oct; 28(10):1569-81. PubMed ID: 17157113
[TBL] [Abstract][Full Text] [Related]
44. Maternal efficacy and safety outcomes in a randomized, controlled trial comparing insulin detemir with NPH insulin in 310 pregnant women with type 1 diabetes.
Mathiesen ER; Hod M; Ivanisevic M; Duran Garcia S; Brøndsted L; Jovanovic L; Damm P; McCance DR;
Diabetes Care; 2012 Oct; 35(10):2012-7. PubMed ID: 22851598
[TBL] [Abstract][Full Text] [Related]
45. Insulin detemir improves glycemic control and reduces hypoglycemia in children with type 1 diabetes: findings from the Turkish cohort of the PREDICTIVE observational study.
Kurtoglu S; Atabek ME; Dizdarer C; Pirgon O; Isguven P; Emek S;
Pediatr Diabetes; 2009 Sep; 10(6):401-7. PubMed ID: 19220776
[TBL] [Abstract][Full Text] [Related]
46. Insulin detemir versus glyburide in women with gestational diabetes mellitus.
Koren R; Ashwal E; Hod M; Toledano Y
Gynecol Endocrinol; 2016 Nov; 32(11):916-919. PubMed ID: 27597308
[TBL] [Abstract][Full Text] [Related]
47. An update on the treatment of type 1 and type 2 diabetes mellitus: focus on insulin detemir, a long-acting human insulin analog.
Raslova K
Vasc Health Risk Manag; 2010 Jun; 6():399-410. PubMed ID: 20539842
[TBL] [Abstract][Full Text] [Related]
48. Differential effects of insulin detemir and neutral protamine Hagedorn (NPH) insulin on hepatic glucose production and peripheral glucose uptake during hypoglycaemia in type 1 diabetes.
Smeeton F; Shojaee Moradie F; Jones RH; Westergaard L; Haahr H; Umpleby AM; Russell-Jones DL
Diabetologia; 2009 Nov; 52(11):2317-23. PubMed ID: 19707744
[TBL] [Abstract][Full Text] [Related]
49. Similar Breast Cancer Risk in Women Older Than 65 Years Initiating Glargine, Detemir, and NPH Insulins.
Bradley MC; Chillarige Y; Lee H; Wu X; Parulekar S; Wernecke M; Bright P; Soukup M; MaCurdy TE; Kelman JA; Graham DJ
Diabetes Care; 2020 Apr; 43(4):785-792. PubMed ID: 32075848
[TBL] [Abstract][Full Text] [Related]
50. The use of insulin analogues in pregnancy.
Lambert K; Holt RI
Diabetes Obes Metab; 2013 Oct; 15(10):888-900. PubMed ID: 23489521
[TBL] [Abstract][Full Text] [Related]
51. A randomized trial comparing the rate of hypoglycemia--assessed using continuous glucose monitoring--in 125 preschool children with type 1 diabetes treated with insulin glargine or NPH insulin (the PRESCHOOL study).
Danne T; Philotheou A; Goldman D; Guo X; Ping L; Cali A; Johnston P
Pediatr Diabetes; 2013 Dec; 14(8):593-601. PubMed ID: 23730996
[TBL] [Abstract][Full Text] [Related]
52. A randomized trial comparing perinatal outcomes using insulin detemir or neutral protamine Hagedorn in type 1 diabetes.
Hod M; Mathiesen ER; Jovanovič L; McCance DR; Ivanisevic M; Durán-Garcia S; Brøndsted L; Nazeri A; Damm P
J Matern Fetal Neonatal Med; 2014 Jan; 27(1):7-13. PubMed ID: 23617228
[TBL] [Abstract][Full Text] [Related]
53. Insulin detemir: a long-acting insulin product.
Jones MC; Patel M
Am J Health Syst Pharm; 2006 Dec; 63(24):2466-72. PubMed ID: 17158694
[TBL] [Abstract][Full Text] [Related]
54. Treatment with insulin detemir or NPH insulin in children aged 2-5 yr with type 1 diabetes mellitus.
Thalange N; Bereket A; Larsen J; Hiort LC; Peterkova V
Pediatr Diabetes; 2011 Nov; 12(7):632-41. PubMed ID: 21418455
[TBL] [Abstract][Full Text] [Related]
55. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes.
Heise T; Nosek L; Rønn BB; Endahl L; Heinemann L; Kapitza C; Draeger E
Diabetes; 2004 Jun; 53(6):1614-20. PubMed ID: 15161770
[TBL] [Abstract][Full Text] [Related]
56. Real-World Analysis of Long-Acting and NPH-Containing Insulins on Glycemic Control.
Hale G; Marcellus V; Benny T; Moreau C; Rosario E; Perez A
Sr Care Pharm; 2024 Jan; 39(1):42-49. PubMed ID: 38160236
[No Abstract] [Full Text] [Related]
57. Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients: the PREDICTIVE BMI clinical trial.
Fajardo Montañana C; Hernández Herrero C; Rivas Fernández M
Diabet Med; 2008 Aug; 25(8):916-23. PubMed ID: 18959604
[TBL] [Abstract][Full Text] [Related]
58. Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naïve people with type 2 diabetes.
Home PD; Bolli GB; Mathieu C; Deerochanawong C; Landgraf W; Candelas C; Pilorget V; Dain MP; Riddle MC
Diabetes Obes Metab; 2015 Jan; 17(1):15-22. PubMed ID: 24957785
[TBL] [Abstract][Full Text] [Related]
59. Safety of insulin glargine use in pregnancy: a systematic review and meta-analysis.
Pollex E; Moretti ME; Koren G; Feig DS
Ann Pharmacother; 2011 Jan; 45(1):9-16. PubMed ID: 21205954
[TBL] [Abstract][Full Text] [Related]
60. Therapy conversion to insulin detemir among patients with type 2 diabetes treated with oral agents: a modeling study of cost-effectiveness in the United States.
Valentine WJ; Erny-Albrecht KM; Ray JA; Roze S; Cobden D; Palmer AJ
Adv Ther; 2007; 24(2):273-90. PubMed ID: 17565917
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
